Aβ Chronic Exposure Promotes an Activation State of Microglia through Endocannabinoid Signalling Imbalance
暂无分享,去创建一个
M. Maccarrone | M. Sergi | M. Nazaré | F. Fanti | S. Oddi | D. Tortolani | Thais Gazzi | L. Scipioni | Francesca Ciaramellano
[1] M. Maccarrone,et al. Determination of endocannabinoids and their conjugated congeners in the brain by means of μSPE combined with UHPLC-MS/MS. , 2023, Talanta.
[2] M. Maccarrone,et al. Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes , 2022, International journal of molecular sciences.
[3] M. Maccarrone,et al. Microglial Endocannabinoid Signalling in AD , 2022, Cells.
[4] H. Spaink,et al. Detection of cannabinoid receptor type 2 in native cells and zebrafish with a highly potent, cell-permeable fluorescent probe , 2022, Chemical science.
[5] D. Mari,et al. Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer’s Disease Patients , 2021, Biomolecules.
[6] Anne-Caroline Schmöle,et al. CB2 Receptor in Microglia: The Guardian of Self-Control , 2020, International journal of molecular sciences.
[7] M. Maccarrone,et al. Bioactive lipids, inflammation and chronic diseases. , 2020, Advanced drug delivery reviews.
[8] T. Bisogno,et al. Cannabinoids and the expanded endocannabinoid system in neurological disorders , 2019, Nature Reviews Neurology.
[9] Maja A. Puchades,et al. Defined astrocytic expression of human amyloid precursor protein in Tg2576 mouse brain , 2018, Glia.
[10] M. T. Grande,et al. Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer’s disease , 2018, Journal of neuroinflammation.
[11] D. Mango,et al. Early alteration of distribution and activity of hippocampal type‐1 cannabinoid receptor in Alzheimer's disease‐like mice overexpressing the human mutant amyloid precursor protein , 2018, Pharmacological research.
[12] Hong Lian,et al. Protocol for Primary Microglial Culture Preparation. , 2016, Bio-protocol.
[13] T. Bisogno,et al. Type-2 cannabinoid receptors in neurodegeneration. , 2016, Pharmacological research.
[14] Burkhard Becher,et al. Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.
[15] D. Holtzman,et al. Three dimensions of the amyloid hypothesis: time, space and 'wingmen' , 2015, Nature Neuroscience.
[16] L. Battistini,et al. Endocannabinoid signalling in innate and adaptive immunity , 2015, Immunology.
[17] M. O’Banion,et al. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed , 2014, Journal of Neuroinflammation.
[18] Mireille Alhouayek,et al. COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. , 2014, Trends in pharmacological sciences.
[19] M. Roth,et al. Differential Expression of Intracellular and Extracellular CB2 Cannabinoid Receptor Protein by Human Peripheral Blood Leukocytes , 2013, Journal of Neuroimmune Pharmacology.
[20] K. Blennow,et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.
[21] D. Nomura,et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. , 2012, Cell reports.
[22] D. Centonze,et al. Effects of palmitoylation of Cys415 in helix 8 of the CB1 cannabinoid receptor on membrane localization and signalling , 2012, British journal of pharmacology.
[23] P. Chameau,et al. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors , 2012, Proceedings of the National Academy of Sciences.
[24] Sean R. Donohue,et al. [125I]SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer’s disease , 2012, Neurochemistry International.
[25] Masahiko Watanabe,et al. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. , 2011, Brain : a journal of neurology.
[26] M. Citron. Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.
[27] N. Stella. Endocannabinoid signaling in microglial cells , 2009, Neuropharmacology.
[28] E. Cudaback,et al. Identification of a Novel Endocannabinoid-Hydrolyzing Enzyme Expressed by Microglial Cells , 2007, The Journal of Neuroscience.
[29] Yun Bai,et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation , 2005, Journal of Neuroinflammation.
[30] Alberto Rábano,et al. Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.
[31] K. Mackie,et al. Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.
[32] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[33] R. Mechoulam,et al. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. , 2000, European journal of pharmacology.
[34] D. Bouvier,et al. Synergistic actions of microglia and astrocytes in the progression of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.
[35] Wan-Wan Lin,et al. Effects of cannabinoids on LPS‐stimulated inflammatory mediator release from macrophages: Involvement of eicosanoids , 2001, Journal of cellular biochemistry.